Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Strategy program "NEXT LEVEL"

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

• Collaboration with MD Anderson Cancer Center, US • Phase I study to evaluate combination of ISR lefitolimod (MGN1703) and checkpoint inhibitor Yervoy® • Combination of immunotherapies could lead to a broader activation of the immune system [more]

Der Vorstand der MOLOGEN AG (ISIN DE0006637200/WKN 663720) weist gemäß § 92 Absatz 1 des Aktiengesetzes darauf hin, dass das vorläufige Eigenkapital der Gesellschaft zum 30. Juni 2016 mit Stand vom 11. Juli 2016 aufgrund eingetretener Verluste nur noch EUR 10.681.859,09 beträgt, womit die Hälfte des EUR 22.631.501,00 betragenden Grundkapitals der... [more]

Estimated Balance as at 30 June 2016 (German version only)
Download PDF

Quarterly Statement as at 31 March 2016
Download PDF

Annual Report 2015
Download PDF

Strategy Program “Next level”

Press Release
Presentation
FAQ